Helix BioPharma Corp. (Helix) is a Canada-based biopharmaceutical company specializing primarily in the field of cancer therapy. The Company is developing products for the treatment and prevention of cancer-based on its technologies. In addition, Helix earns revenues from its drug distribution business in Canada and international licensing activities. Helix’s product development initiatives include its L-DOS47 and Topical Interferon Alpha-2b new drug candidates. Helix’s L-DOS47 is a new drug in development that offers an approach to the treatment of lung cancer. Helix is developing Topical Interferon Alpha-2b for the treatment of low-grade cervical lesions and ano-genital warts (AGW) caused by Human Papilloma Virus (HPV) infections. Helix is also conducting a Phase II clinical trial of Topical Interferon Alpha-2b in patients with AGW at multiple centers in Sweden and Germany. Its products include Orthovisc, Imunovir and Gastrointestinal products, including the Company’s own Klean-Prep.